Physician

Wade Michael Smith, M.D.

According to 2025 Medicare claims, Wade Smith, M.D. (NPI: 1730240219) practices medical oncology in the Anaheim-Santa Ana-Irvine, CA market, with the plurality of this provider's patient population coming from Orange, CA. This provider's primary affiliated billing organization is CITY OF HOPE MEDICAL FOUNDATION (NPI: 1871886366; TIN: 274803222) and primary practice location at 92660-7725.

Smith's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 485 traditional Medicare patients, billed 189,302 HCPCS/CPT codes, and received $3,363,788 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 342 prescription claims across 94 beneficiaries totaling $923,824 in drug costs, led by Verzenio (Abemaciclib). DME data shows 42 claims. Open Payments data shows 4 records totaling $165,525. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $505,323 to $3,363,788. Similarly, Part D prescription costs have risen steadily, from $9,478 to $923,824. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	139	38,940	$505,323
2016	146	31,219	$421,363
2017	187	40,051	$543,304
2018	180	27,576	$347,381
2019	160	12,534	$152,842
2020	129	47,713	$993,823
2021	234	94,744	$1,719,715
2022	334	115,048	$1,733,570
2023	465	173,270	$2,518,042
2024	485	189,302	$3,363,788

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	58	227	$9,478
2016	74	285	$53,313
2017	82	380	$90,225
2018	78	376	$88,402
2019	83	392	$259,482
2020	47	167	$132,706
2021	47	140	$301,341
2022	58	182	$126,075
2023	64	232	$390,600
2024	94	342	$923,824

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	28	$10,209
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	42	$1,245

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	82	344	$122
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	151	418	$104
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	84	104	$70
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	83	106	$14
96372	Injection of drug or substance under skin or into muscle	91	238	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Verzenio	Abemaciclib	11	308	$164,168
Zarxio	Filgrastim-Sndz	16	409	$42,440
Letrozole	Letrozole	68	5,310	$1,669
Exemestane	Exemestane	23	1,380	$1,534
Tamoxifen Citrate	Tamoxifen Citrate	31	2,003	$620

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	23	$888
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$358

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$43	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$165,482	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Wade Michael Smith, M.D.?

Tedicare shows public-source Medicare data for Wade Michael Smith, M.D. (NPI 1730240219), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Wade Michael Smith, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Wade Michael Smith, M.D.?

Wade Michael Smith, M.D. is linked to CITY OF HOPE MEDICAL FOUNDATION (billing NPI 1871886366) in the available physician profile data.

Does Wade Michael Smith, M.D. have Open Payments data?

Wade Michael Smith, M.D. has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.